本音で語る！　リウマチ・膠原病治療薬の使い方

出版社： 羊土社
著者：
発行日： 2020-09-14
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784758118811
電子書籍版： 2020-09-25 （第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,500 円(税込)

購入する

商品紹介

関節リウマチの治療薬を使い勝手に特化して解説！関連疾患に使われる薬までフォローし，投与スケジュールやモニターなど治療に必要な情報がパッとわかる，エキスパートの本音がわかる一冊です．

目次

  • 第1章　治療アルゴリズム
    １　関節リウマチ ～EULAR recommendations 2019
    ２　脊椎関節炎 ～ASUS-EULAR recommendations 2016
    ３　乾癬性関節炎（関節症性乾癬） ～EULAR recommendations 2019

    第2章　関節リウマチに使用される薬剤
    　１　グルココルチコイド　
    　２　NSAIDs　非ステロイド性抗炎症薬
    　３　csDMARDs　従来型合成抗リウマチ薬
    　４　bDMARDs　生物学的製剤
    　５　tsDMARDs　分子標的型抗リウマチ薬

    第3章　関連疾患に使用される薬剤
    　１　ヒドロキシクロロキン
    　２　生物学的製剤
    　３　免疫抑制剤・その他
    　４　免疫グロブリン
    　５　骨粗鬆症薬

    第4章　Case Study 患者背景に応じた処方
    　１　MTX使用困難のとき治療はどうする？
    　２　背景リスクのある患者-1　感染症
    　３　背景リスクのある患者-2　癌の既往または治療中
    　４　妊娠希望の患者や，妊婦・授乳婦への処方
    　５　周術期の治療
    　６　高齢発症関節リウマチの治療，在宅での治療
    　７　ワクチンと治療
    　８　併存疾患と治療　心血管リスク・血栓塞栓症リスク

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 治療アルゴリズム

P.14 掲載の参考文献
1) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis, 79 : 685-699, 2020
PubMed
2) Smolen JS, et al : Treating rheumatoid arthritis to target : 2014 update of the recommendations of an international task force. Ann Rheum Dis, 75 : 3-15, 2016
PubMed
P.20 掲載の参考文献
1) Rudwaleit M, et al : The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis, 70 : 25-31, 2011
PubMed
2) Smolen JS, et al : Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target : 2017 update of recommendations by an international task force. Ann Rheum Dis, 77 : 3-17, 2018
PubMed
3) van der Heijde D, et al : 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis, 76 : 978-991, 2017
PubMed
4) Sieper J & Poddubnyy D : Axial spondyloarthritis. Lancet, 390 : 73-84, 2017
PubMed
5) Kiltz U, et al : Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Ann Rheum Dis, 79 : 193-201, 2020
PubMed
6) 岸本暢将, 他 : 脊椎関節炎. 日内会誌, 103 : 2431-2439, 2014
 
P.24 掲載の参考文献
1) 日本皮膚科学会乾癬性関節炎診療ガイドライン作成委員会, 他 : 乾癬性関節炎診療ガイドライン 2019. 日皮会誌, 129 : 2675-2733, 2019
 
2) Gossec L, et al : EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies : 2019 update. Ann Rheum Dis, 79 : 700-712, 2020
PubMed
3) Coates LC, et al : Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol, 68 : 1060-1071, 2016
 

第2章 関節リウマチに使用される薬剤

P.30 掲載の参考文献
1) Buttgereit F, et al : Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens : current questions and tentative answers in rheumatology. Ann Rheum Dis, 61 : 718-722, 2002
PubMed
2) West SG : Glucocorticoids-Systemic and Injectable.「Rheumatology Secrets 4 ed」 (West SG), ELSEVIER, 2014
 
3) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis, 78 : 736-745, 2019
 
4) Johannes WG Jacobs & Johannes WJ Bijlsma : Glucocorticoid Therapy.「Kelley and Firestein's Textbook of Rheumatology 10th edition」 (Firestein GS, et al/eds), pp932-957, Elsevier, 2016
 
P.42 掲載の参考文献
1) van der Heijde D, et al : 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis, 76 : 978-991, 2017
PubMed
2) Lanza FL, et al : Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol, 104 : 728-738, 2009
 
3) Trelle S, et al : Cardiovascular safety of non-steroidal anti-inflammatory drugs : network meta-analysis. BMJ, 342 : c7086, 2011
PubMed
4) Solomon SD, et al : Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med, 352 : 1071-1080, 2005
 
5) Nissen SE, et al : Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med, 375 : 2519-2529, 2016
 
P.49 掲載の参考文献
1) 「関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン 2016年改訂版」 (日本リウマチ学会, 他/編), 羊土社, 2016
 
2) 「リウマトレックス適正使用情報 Vol.12」 (ワイス株式会社), 2007
 
3) 日本リウマチ学会 : メトトレキサートを服用する患者さんへ 第2版, 2017 https://www.ryumachi-jp.com/pdf/mtx_2017.pdf
 
4) Shea B, et al : Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev : CD000951, 2013
PubMed
5) Brown PM, et al : Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol, 12 : 731-742, 2016
PubMed
6) Takahashi C, et al : Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis : a 76-week prospective study. RMD Open, 3 : e000363, 2017
PubMed
7) Ridker PM, et al : Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med, 380 : 752-762, 2019
PubMed
P.53 掲載の参考文献
8) Nunokawa T, et al : Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in patients with rheumatoid arthritis : A nested case-control study. Semin Arthritis Rheum, doi : 10.1016/j.semarthrit.2018.05.013. [Epub ahead of print], 2018
 
9) Lee CK, et al : Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum, 50 : 3831-3843, 2004
PubMed
10) Rodenburg RJ, et al : The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum, 43 : 1941-1950, 2000
PubMed
11) Plosker GL & Croom KF : Sulfasalazine : a review of its use in the management of rheumatoid arthritis.Drugs, 65a (13) : 1825-1849, 2005
 
P.55 掲載の参考文献
12) Ichikawa Y, et al : Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis : a multicenter, double-blind, randomized controlled study. Mod Rheumatol, 15 : 323-328, 2005
PubMed
13) Bykerk VP : Nonimmunosuppressive disease-modifying antirheumatic drugs.「Rheumatology 6th edition」 (Hochberg M, et al/eds), pp434-442, Mosby, 2014
 
P.58 掲載の参考文献
14) Hara M, et al : Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis : a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol, 17 : 1-9, 2007
 
15) Hara M, et al : Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate : an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol, 24 : 410-418, 2014
PubMed
16) 田中啓一, 他 : 低分子抗リウマチ薬イグラチモド (コルベット(R) /ケアラム錠(R) 25mg) の薬理学的特性および臨床試験成績. 日薬理誌, 140 : 285-292, 2012 https://www.jstage.jst.go.jp/article/fpj/140/6/140_285/_pdf
 
P.61 掲載の参考文献
17) Miceli-Richard C & Dougados M : Leflunomide for the treatment of rheumatoid arthritis. Expert Opin Pharmacother, 4 : 987-997, 2003
PubMed
18) Sawada T, et al : Leflunomide-induced interstitial lung disease : prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford), 48 : 1069-1072, 2009
PubMed
P.64 掲載の参考文献
19) Fleischmann R, et al : Tacrolimus in rheumatoid arthritis. Expert Opin Pharmacother, 7 : 91-98, 2006
PubMed
P.66 掲載の参考文献
1) Smolen JS & Aletaha D : Rheumatoid arthritis therapy reappraisal : strategies, opportunities and challenges. Nat Rev Rheumatol, 11 : 276-289, 2015
PubMed
2) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis, 79 : 685-699, 2020
PubMed
3) Sokolove J, et al : Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab : 2-year results from the AMPLE trial. Ann Rheum Dis, 75 : 709-714, 2016
PubMed
4) Ozen G, et al : Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis : data from an observational study. Arthritis Res Ther, 21 : 141, 2019
PubMed
P.70 掲載の参考文献
5) 「関節リウマチ (RA) に対するTNF阻害薬使用の手引き (2020.2改訂版) 」 (日本リウマチ学会, 他/編), 2020 https://www.ryumachi-jp.com/info/guideline_tnf.pdf
 
6) 「B型肝炎治療ガイドライン (第3.1版) 」 (日本肝臓学会, 他/編), 2019 https://www.jsh.or.jp/files/uploads/HBV_GL_ver3.1_v1.2-1__2.pdf
 
7) Koike T, et al : Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol, 21 : 343-351, 2011
PubMed
8) Takeuchi T, et al : Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis, 67 : 189-194, 2008
PubMed
9) Koike T, et al : Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : postmarketing surveillance report of 7740 patients. Mod Rheumatol, 24 : 390-398, 2014
PubMed
10) Kanbori M, et al : Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis. Mod Rheumatol, 28 : 66-75, 2018
PubMed
11) Kameda H, et al : Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis : Interim analysis of post-marketing surveillance. Nihon Rinsho Meneki Gakkai Kaishi, 40 : 196-205, 2017
PubMed
12) Harigai M, et al : Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population : A nationwide cohort study in Japan. Mod Rheumatol, 26 : 642-650, 2016
 
13) Furer V, et al : 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis, 79 : 239-52, 2020
 
P.72 掲載の参考文献
14) Smolen JS, et al : Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE) : a randomised controlled trial. Lancet, 381 : 918-929, 2013
 
15) Murashima A, et al : Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis : drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis, 68 : 1793-1794, 2009
 
16) Gotestam Skorpen C, et al : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis, 75 : 795-810, 2016
PubMed
P.75 掲載の参考文献
17) Takeuchi T, et al : Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis : results from the RISING study. Mod Rheumatol, 19 : 478-487, 2009
 
18) Tanaka Y, et al : Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis, 69 : 1286-1291, 2010
PubMed
P.77 掲載の参考文献
19) Smolen JS, et al : Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone : the randomised controlled OPTIMA trial. Lancet, 383 : 321-332, 2014
PubMed
20) Burmester GR, et al : Efficacy and safety of ascending methotrexate dose in combination with adalimumab : the randomised CONCERTO trial. Ann Rheum Dis, 74 : 1037-1044, 2015
PubMed
P.79 掲載の参考文献
21) Tanaka Y, et al : Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis : results of the GO-FORTH study. Ann Rheum Dis, 71 : 817-824, 2012
PubMed
P.81 掲載の参考文献
16) Gotestam Skorpen C, et al : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis, 75 : 795-810, 2016
PubMed
P.86 掲載の参考文献
6) 「B型肝炎治療ガイドライン (第3.1版) 」 (日本肝臓学会, 他/編), 2019 https://www.jsh.or.jp/files/uploads/HBV_GL_ver3.1_v1.2-1__2.pdf
 
22) 「関節リウマチ (RA) に対するIL-6阻害薬使用ガイドライン (2020年2月20日改訂版) 」(日本リウマチ学会, 他/編), 2020 https://www.ryumachi-jp.com/info/guideline_tcz.pdf
 
23) Nishimoto N, et al : Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis : meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol, 20 : 222-232, 2010
PubMed
P.90 掲載の参考文献
6) 「B型肝炎治療ガイドライン (第3.1版) 」 (日本肝臓学会, 他/編), 2019 https://www.jsh.or.jp/files/uploads/HBV_GL_ver3.1_v1.2-1__2.pdf
 
24) 「関節リウマチ (RA) に対するアバタセプト使用の手引き (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_abt.pdf
 
25) Singh JA, et al : Adverse effects of biologics : a network meta-analysis and Cochrane overview.Cochrane Database Syst Rev, 2 : CD008794, 2011
PubMed
26) Westhovens R, et al : Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate : a 5-year extended phase IIB study. J Rheumatol, 36 : 736-742, 2009
PubMed
27) オレンシア(R) 点滴静注用250mg インタビューフォーム 2020年2月改訂 (第10版) http://file.bmshealthcare.jp/orencia/renewal/pdf/IF_ORIV2002.pdf
 
28) Simon TA, et al : Malignancies in the rheumatoid arthritis abatacept clinical development programme : an epidemiological assessment. Ann Rheum Dis, 68 : 1819-1826, 2009
PubMed
29) Weinblatt M, et al : Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs : A one-year randomized, placebo-controlled study. Arthritis Rheum, 54 : 2807-2816, 2006
PubMed
P.102 掲載の参考文献
1) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis, 79 : 685-699, 2020
PubMed
2) 「全例市販後調査のためのバリシチニブ適正使用ガイド (2020年2月1日改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_barishichinibu.pdf
 
3) 「全例市販後調査のためのトファシチニブ使用ガイド (2020年2月1日改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_tofacitinib.pdf
 
4) 「全例市販後調査のためのペフィシチニブ使用ガイド (2020年2月1日改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_peficitinib.pdf
 
5) 「全例市販後調査のためのウパダシチニブ適正使用ガイド」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/publish/guide/guideline_upadacitinib/
 
6) Schwartz DM, et al : JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov, 16 : 843-862, 2017
PubMed
P.106 掲載の参考文献
1) Schett G, et al : Tapering biologic and conventional DMARD therapy in rheumatoid arthritis : current evidence and future directions. Ann Rheum Dis, 75 : 1428-1437, 2016
PubMed
2) Singh JA, et al : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol, 68 : 1-26, 2016
PubMed
3) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2016 update. Ann Rheum Dis, 76 : 960-977, 2017
PubMed
4) Verhoef LM, et al : The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis : a mixed methods study. Rheumatology (Oxford), 57 : 1947-1955, 2018
PubMed

第3章 関連疾患に使用される薬剤

P.110 掲載の参考文献
1) Fanouriakis A, et al : 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis, 78 : 736-745, 2019
PubMed
2) Ruiz-Irastorza G, et al : Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus : a systematic review. Ann Rheum Dis, 69 : 20-28, 2010
PubMed
3) Shippey EA, et al : Hydroxychloroquine : An old drug with new relevance. Cleve Clin J Med, 85 : 459-467, 2018
PubMed
4) 「皮膚エリテマトーデスおよび全身性エリテマトーデスに対するヒドロキシクロロキン使用のための簡易ガイドライン (2015.10.20版) 」 (日本リウマチ学会/編) https://www.ryumachi-jp.com/info/guideline_hcq.pdf
 
5) 「ヒドロキシクロロキン適正使用の手引き (簡易版) (2015.10.20版) 」 (日本皮膚科学会/編) https://www.ryumachi-jp.com/info/guideline_hcq.pdf
 
P.117 掲載の参考文献
1) Stone JH, et al : Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med, 363 : 221-232, 2010
PubMed
2) Guillevin L, et al : Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med, 371 : 1771-1780, 2014
PubMed
3) Charles P, et al : Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission : results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis, 77 : 1143-1149, 2018
PubMed
4) 2019 ACR/ARP Annual Meeting : 2019 ACR/ARP Annual Meeting Abstract Supplement. Arthritis Rheumatol, 71 Suppl 10 : 1-5362, 2019
 
P.120 掲載の参考文献
5) van Vollenhoven RF, et al : Belimumab in the treatment of systemic lupus erythematosus : high disease activity predictors of response. Ann Rheum Dis, 71 : 1343-1349, 2012
PubMed
6) Bruce IN, et al : Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus, 25 : 699-709, 2016
PubMed
7) Navarra SV, et al : Efficacy and safety of belimumab in patients with active systemic lupus erythematosus : a randomised, placebo-controlled, phase 3 trial. Lancet, 377 : 721-731, 2011
PubMed
8) Furie R, et al : A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum, 63 : 3918-3930, 2011
 
9) Doria A, et al : Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol, 70 : 1256-1264, 2018
PubMed
P.124 掲載の参考文献
10) Wechsler ME, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 376 (20) : 1921-1932, 2017
 
11) Steinfeld J, et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.J Allergy Clin Immunol. 143 (6) : 2170-2177, 2018
PubMed
P.127 掲載の参考文献
12) Gordon KB, et al : Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med, 375 : 345-356, 2016
PubMed
13) Saeki H, et al : Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis : Results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol, 44 : 355-362, 2017
 
14) Taams LS, et al : IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol, 14 : 453-466, 2018
PubMed
P.129 掲載の参考文献
15) Kishimoto M, et al : Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis : 24-week results from an open-label phase 3 study (MEASURE 2-J). Mod Rheumatol, 30 : 132-140, 2020
PubMed
P.132 掲載の参考文献
16) McInnes IB, et al : Efficacy and safety of ustekinumab in patients with active psoriatic arthritis : 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet, 382 : 780-789, 2013
PubMed
17) Griffiths CE, et al : Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med, 362 : 118-128, 2010) 23769296
PubMed
18) Onuora S : Therapy : Ustekinumab after anti-TNF failure : a step closer to the PSUMMIT of psoriatic arthritis therapy? Nat Rev Rheumatol, 10 : 125, 2014
 
P.137 掲載の参考文献
19) van der Hilst JCh, et al : Efficacy of anti-IL-1 treatment in familial Mediterranean fever : a systematic review of the literature. Biologics, 10 : 75-80, 2016
PubMed
20) Dinarello CA : The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol, 15 : 612-632, 2019
PubMed
P.142 掲載の参考文献
1) Kakuta Y, et al : Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia : prospects for clinical application of NUDT15 genotyping. J Gastroenterol, 53 : 172-180, 2018
PubMed
2) Kakuta Y, et al : NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease : a multicenter study. J Gastroenterol, 53 : 1065-1078, 2018
PubMed
3) 「リウマチ性疾患に対するアザチオプリン使用に関する通知 (NUDT15遺伝子多型検査の保険承認を受けて) 」 (山本一彦, 他/編), 2019 https://www.ryumachi-jp.com/info/news190222.pdf
 
P.145 掲載の参考文献
4) 「Mycophenolate : Overview of use and adverse effects in the treatment of rheumatic diseases」 (Seo P, et al/eds), UpToDate, 2019 https://www.uptodate.com/contents/mycophenolate-overview-of-use-and-adverseeffects-in-the-treatment-of-rheumatic-diseases
 
5) Jacob MVL : Immunosuppressive Drugs.「Kelley and Firestein's Textbook of Rheumatology 10th edition」 (Firestein GS, et al/eds), pp983-998, Elsevier, 2017
 
6) Allem KB & Keating RM : Immunosuppressive agents : cyclosporine, cyclophosphamide, azathioprine, mycophenolate mofetil, and tacrolimus.「Rheumatology, 7th ed」(Hochberg M, et al/eds), pp518-526, Elsevier, 2018
 
7) Roos N, et al : In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther, 321 : 583-589, 2007
PubMed
P.148 掲載の参考文献
8) 岸本暢将, 他 : ミゾリビン (MZR). 「関節リウマチの診かた, 考えかた ver.3」 (岸本暢将, 岡田正人/編), pp261-264, 中外医学社, 2018
 
9) 中崎聡, 他 : メトトレキサート効果不十分例に低用量ミゾリビンパルス療法を 追加併用た関節リウマチ患者の有効性と安全性の検討-後ろ向き研究-. 臨床リウマチ, 23 : 88-94, 2011
 
10) 小熊麻子, 澤部琢哉 : 生物学的製剤抵抗性関節リウマチに対するミゾリビンパルス療法併用の効果. 臨床リウマチ, 25 : 20-27, 2013
 
P.150 掲載の参考文献
11) Choc MG : Bioavailability and pharmacokinetics of cyclosporine formulations : Neoral vs Sandimmune. Int J Dermatol, 36 Suppl 1 : 1-6, 1997
PubMed
12) Bertsias GK, et al : Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis, 71 : 1771-1782, 2012
 
13) Faul C, et al : The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med, 14 : 931-938, 2008
PubMed
P.153 掲載の参考文献
12) Bertsias GK, et al : Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis, 71 : 1771-1782, 2012
 
14) Mok CC, et al : Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis : a randomised controlled trial and long-term follow-up. Ann Rheum Dis, 75 : 30-36, 2016
PubMed
15) Zhang H, et al : Multitarget Therapy for Maintenance Treatment of Lupus Nephritis. J Am Soc Nephrol, 28 : 3671-3678, 2017
PubMed
16) Lampropoulos CE, et al : Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus : a possible alternative. Rheumatology (Oxford), 43 : 1383-1385, 2004
PubMed
17) Kurita T, et al : The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford), 54 : 39-44, 2015
 
P.159 掲載の参考文献
18) Boumpas DT, et al : Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet, 340 : 741-745, 1992
PubMed
19) Houssiau FA, et al : Immunosuppressive therapy in lupus nephritis : the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum, 46 : 2121-2131, 2002
 
20) de Groot K, et al : Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis : a randomized trial. Ann Intern Med, 150 : 670-680, 2009
PubMed
21) Pagnoux C, et al : Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older : results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol, 67 : 1117-1127, 2015
PubMed
22) Ntatsaki E, et al : BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford), 53 : 2306-2309, 2014
PubMed
23) Yates M, et al : EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis, 75 : 1583-1594, 2016
 
24) 「ANCA関連血管炎診療ガイドライン 2017」 (厚生労働科学研究費補助金 難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性血管炎に関する調査研究班, 他/編), 診断と治療社, 2017
 
25) 「全身性エリテマトーデス診療ガイドライン 2019」 (厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究 (自己免疫班), 他/編), 南山堂, 2019
 
26) Fanouriakis A, et al : 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis, 79 : 713-723, 2020
 
P.163 掲載の参考文献
27) Cauli A, et al : Clinical potential of apremilast in the treatment of psoriatic arthritis. Immunotargets Ther, 3 : 91-96, 2014
PubMed
28) 「オテズラ適正使用ガイド」 (セルジーン株式会社), 2018
 
29) 日本皮膚科学会乾癬性関節炎診療ガイドライン作成委員会, 他 : 乾癬性関節炎診療ガイドライン 2019. 日皮会誌, 129 : 2675-2733, 2019
 
30) Crowley J, et al : Long-term safety and tolerability of apremilast in patients with psoriasis : Pooled safety analysis for > 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol, 77 : 310-317.e1, 2017
 
31) Hatemi G, et al : Trial of Apremilast for Oral Ulcers in Behcet's Syndrome. N Engl J Med, 381 : 1918-1928, 2019
PubMed
32) De Luca G, et al : Efficacy and safety of apremilast for Behcet's syndrome : a real-life single-centre Italian experience. Rheumatology (Oxford), 59 : 171-175, 2020
PubMed
P.167 掲載の参考文献
33) Becker ML, et al : Pharmacology and Drug Therapy : Nonbiologic Therapies.「Textbook of Pediatric Rheumatology 7th Edition」 (Petty R, et al/eds), pp140-160, Saunders, 2015
 
34) Terkeltaub R : Management of gout and hyperuricemia.「Rheumatology, 2-Volume Set 7th Edition」 (Hochberg M, et al/eds), pp1613-1620, Elsevier, 2018
 
35) Colchicine. Drug Information Provided By Gold Standard. 2019 https://www.elsevier.com/searchresults?query=Colchicine%20Drug%20Information&labels=all&page=1
 
36) 三澤拓馬, 他 : NLRP3 インフラマソームと痛風関節炎. Gout and Nucleic Acid Metabolism, 39 : 1-6, 2015 https://www.jstage.jst.go.jp/article/gnam/39/1/39_1/_pdf/-char/ja
 
37) Tardif JC, et al : Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med, 381 : 2497-2505, 2019
PubMed
P.170 掲載の参考文献
38) Flaherty KR, et al : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med, 381 : 1718-1727, 2019
PubMed
39) 「診断・治療指針 2020」 (日本呼吸器学会・日本リウマチ学会合同 膠原病に伴う間質性肺疾患 診断・治療指針 2020 作成委員会), 2020
 
P.176 掲載の参考文献
1) Mori M, et al : Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease. Mod Rheumatol, 14 : 361-366, 2004
PubMed
2) Kobayashi T, et al : Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study) : a randomised, open-label, blinded-endpoints trial. Lancet, 379 : 1613-1620, 2012
PubMed
3) Miyasaka N, et al : Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids : a randomized double-blind placebo-controlled trial. Mod Rheumatol, 22 : 382-393, 2012
PubMed
4) Koike H, et al : Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) : a multicenter, double-blind trial. J Neurol, 262 : 752-759, 2015
 
5) Mulhearn B & Bruce IN : Indications for IVIG in rheumatic diseases. Rheumatology (Oxford), 54 : 383-391, 2015
PubMed
6) Bayry J, et al : Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol, 7 : 349-359, 2011
PubMed
7) McCrindle BW, et al : Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease : A Scientific Statement for Health Professionals From the American Heart Association. Circulation, 135 : e927-e999, 2017
PubMed
8) Anh-Tu Hoa S & Hudson M : Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies. Semin Arthritis Rheum, 46 : 488-508, 2017
PubMed
P.185 掲載の参考文献
1) 「骨粗鬆症の予防と治療ガイドライン 2015年度版」 (日本骨粗鬆症学会, 他/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
 
2) 「ステロイド性骨粗鬆症の管理と治療ガイドライン 2014年改訂版」 (日本骨代謝学会, 他/編), 大阪大学出版会, 2014
 
3) Nayak S & Greenspan SL : Osteoporosis Treatment Efficacy for Men : A Systematic Review and Meta-Analysis. J Am Geriatr Soc, 65 : 490-495, 2017
 
4) Buckley L, et al : 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken), 69 : 1095-1110, 2017
PubMed
5) Compston JE, et al : Osteoporosis. Lancet, 393 : 364-376, 2019
PubMed
6) Confavreux CB, et al : Persistence at 1 year of oral antiosteoporotic drugs : a prospective study in a comprehensive health insurance database. Eur J Endocrinol, 166 : 735-741, 2012
 
7) 「骨吸収抑制薬関連顎骨壊死の病態と管理 : 顎骨壊死検討委員会ポジションペーパー 2016」 (顎骨壊死検討委員会 (委員長 米田俊之)/編), 日本骨代謝学会, 2016
 
8) Black DM & Rosen CJ : Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med, 374 : 254-262, 2016
PubMed
9) McClung M, et al : Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone, 41 : 122-128, 2007
PubMed
10) Dell RM, et al : Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res, 27 : 2544-2550, 2012
PubMed
11) Black DM, et al : Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med, 383 : 743-753, 2020
PubMed
12) Adler RA, et al : Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment : Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res, 31 : 16-35, 2016
 
13) Rodan G, et al : Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin, 20 : 1291-1300, 2004
PubMed
P.190 掲載の参考文献
1) 「骨粗鬆症の予防と治療ガイドライン 2015年版」 (骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
 
4) Buckley L, et al : 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken), 69 : 1095-1110, 2017
PubMed
8) Black DM & Rosen CJ : Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med, 374 : 254-262, 2016
PubMed
14) テリボン皮下注 28.2 μg オートインジェクター 添付文書, 2019年9月作成 (第1版)
 
15) Miller PD, et al : Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis : A Randomized Clinical Trial. JAMA, 316 : 722-733, 2016
PubMed
16) Nakamura T, et al : Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab, 97 : 3097-3106, 2012
 
17) 上野正喜, 他 : バルーンカイフォプラスティー後の続発性椎体骨折に対する週1回皮下注射製剤テリパラチドの有用性. Journal of Spine Research, 4 : 1399-1404, 2013
Medical*Online
18) Leder BZ, et al : Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study) : extension of a randomised controlled trial. Lancet, 386 : 1147-1155, 2015
PubMed
P.195 掲載の参考文献
4) Buckley L, et al : 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken), 69 : 1095-1110, 2017
PubMed
19) Eastell R, et al : Pharmacological Management of Osteoporosis in Postmenopausal Women : An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab, 104 : 1595-1622, 2019
PubMed
20) プラリア皮下注60mg シリンジ 添付文書 2020年3月改訂 (第2版) https://pins.japic.or.jp/pdf/newPINS/00061356.pdf
 
21) 「関節リウマチに対するデノスマブ使用の手引き (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_denosumab.pdf
 
P.199 掲載の参考文献
22) Shoback D, et al : Pharmacological Management of Osteoporosis in Postmenopausal Women : An Endocrine Society Guideline Update. J Clin Endocrinol Metab, 105 : dgaa048, 2020
PubMed
23) Saag KG, et al : Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med, 377 : 1417-1427, 2017
 
24) Langdahl BL, et al : Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy : a randomised, open-label, phase 3 trial. Lancet, 390 : 1585-1594, 2017
PubMed
25) Bovijn J, et al : Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci Transl Med, 12 : aay6570, 2020
PubMed
26) 「イベニティ皮下注105mgシリンジ」 (医薬品医療機器情報提供) https://www.info.pmda.go.jp/go/pack/3999449G1025_1_04/
 
27) Xiong J & O'Brien CA : Osteocyte RANKL : new insights into the control of bone remodeling. J Bone Miner Res, 27 : 499-505, 2012
 
P.203 掲載の参考文献
22) Shoback D, et al : Pharmacological Management of Osteoporosis in Postmenopausal Women : An Endocrine Society Guideline Update. J Clin Endocrinol Metab, 105 : doi : 10.1210/clinem/dgaa048, 2020
 
28) Siris ES, et al : Skeletal effects of raloxifene after 8 years : results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res, 20 : 1514-1524, 2005
PubMed
29) Peng L, et al : Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis : A systematic review and meta-analysis. Medicine (Baltimore), 96 : e8659, 2017
PubMed

第4章 Case Study 患者背景に応じた処方

P.213 掲載の参考文献
1) 「関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン 2016年改訂版」 (日本リウマチ学会 MTX 診療ガイドライン策定小委員会/編), 羊土社, 2016
 
2) 「B型肝炎治療ガイドライン (第3版) 2019年3月」 (日本肝臓学会, 肝炎診療ガイドライン作成委員会/編), 2019 https://www.jsh.or.jp/files/uploads/HBV_GL_ver3.1_v1.2-1__2.pdf
 
3) Lindor KD, et al : Primary Biliary Cholangitis : 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 69 : 394-419, 2019
 
4) LaBrecque DR, et al : World Gastroenterology Organisation global guidelines : Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol, 48 : 467-473, 2014
PubMed
5) Demoruelle MK, et al : Connective tissue disease-related interstitial lung disease. Best Pract Res Clin Rheumatol, 30 : 39-52, 2016
PubMed
6) Bes C : Comprehensive review of current diagnostic and treatment approaches to interstitial lung disease associated with rheumatoid arthritis. Eur J Rheumatol, 6 : 146-149, 2018
PubMed
7) Roubille C & Haraoui B : Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis : a systematic literature review. Semin Arthritis Rheum, 43 : 613-626, 2014
PubMed
8) Jani M, et al : The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol, 10 : 284-294, 2014
PubMed
P.239 掲載の参考文献
1) Pollicino T & Raimondo G : Occult hepatitis B infection. J Hepatol, 61 : 688-689, 2014
PubMed
2) Oketani M, et al : Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan : Summary of the annual nationwide survey between 2004 and 2009. Hepatol Res, 43 : 97-105, 2013
PubMed
3) Sugawara K, et al : Acute liver failure in Japan : definition, classification, and prediction of the outcome. J Gastroenterol, 47 : 849-861, 2012
PubMed
4) Perrillo RP, et al : American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology, 148 : 221-244.e3, 2015
 
5) 坪内博仁, 他 : 免疫抑制剤・化学療法により発症するB型肝炎対策. 肝臓, 50 : 38-42, 2009
 
6) Pmda 報告いただいた副作用報告に関する情報
 
7) 「B型肝炎ウイルス感染リウマチ性疾患患者への免疫抑制療法に関する提言」 (日本リウマチ学会/編), 2014
 
8) Singh JA, et al : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol, 68 : 1-26, 2016
PubMed
8) Jensen PA, et al : Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep, 54 : 1-141, 2005
PubMed
9) 「関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン 2016年改訂版」(日本リウマチ学会MTX 診療ガイドライン策定小委員会/編), 羊土社, 2016
 
10) 「関節リウマチ (RA) に対する TNF 阻害薬使用の手引き (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_tnf.pdf
 
11) 「関節リウマチ (RA) に対するIL-6阻害薬使用の手引き (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_IL-6.pdf
 
12) 「関節リウマチ (RA) に対するアバタセプト使用の手引き (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_abt.pdf
 
13) 「全例市販後調査のためのペフィシチニブ使用ガイドライン」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_peficitinib.pdf
 
14) 「全例市販後調査のためのバリシチニブ適正使用ガイド (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_barishichinibu.pdf
 
15) 「全例市販後調査のためのトファシチニブ適正使用ガイド (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_tofacitinib.pdf
 
16) Till JE, et al : Finding Canadian cancer clinical trials on the Internet : an exploratory evaluation of online resources. CMAJ, 168 : 1127-1129, 2003
PubMed
17) American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC) : Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med, 161 : S221-S247, 2000
 
19) Dheda K, et al : Tuberculosis. Lancet, 387 : 1211-1226, 2016
PubMed
20) 日本結核病学会予防委員会・治療委員会 : 潜在性結核感染症治療指針. 結核, 88 : 497-512, 2013 https://www.kekkaku.gr.jp/pub/Vol.88(2013)/Vol88_No5/Vol88No5P497-512.pdf
 
21) Arkema EV, et al : Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis, 74 : 1212-1217, 2015
 
22) 「炎症性疾患に対する生物学的製剤と呼吸器疾患 診療の手引き 改訂第2版」 (日本呼吸器学会, 他/編), 2020
 
23) David M. Lewinsohn, et al : Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines : Diagnosis of Tuberculosis in Adults and Children. CID, 64 : e1-e33, 2017 https://www.thoracic.org/statements/resources/tb-opi/diagnosis-of-tuberculosis-inadults-and-children.PDF
 
24) Pai M, et al : Systematic review : T-cell-based assays for the diagnosis of latent tuberculosis infection : an update. Ann Intern Med, 149 : 177-184, 2008
 
25) T-スポット(R). TB添付文書 (2017.1 改訂第8版) https://www.tspot-tb.jp/product/download/pdf/PI-TB-JP-V8.pdf
 
26) Anibarro L, et al : Interferon-γ release assays in tuberculosis contacts : is there a window period? Eur Respir J, 37 : 215-217, 2011
 
27) 「感染症法に基づく結核の接触者健康診断の手引き (改訂第5版) 」 (厚生労働科学研究 (新型インフルエンザ等新興・再興感染症研究事業)/編), 2014 https://jata.or.jp/rit/rj/2014.3sessyokusya1.pdf
 
28) 小橋吉博 : 抗結核薬に対する減感作療法について. 結核, 75 : 521-526, 2000 https://www.kekkaku.gr.jp/pub/Vol.88(2013)/Vol88_No5/Vol88No5P497-512.pdf
 
29) 2018 surveillance (exceptional review) of tuberculosis (NICE guideline NG33), 2018 https://www.nice.org.uk/guidance/ng33/resources/2018-surveillance-exceptionalreview-of-tuberculosis-nice-guideline-ng33-pdf-8546425319365
 
30) International Union Against Tuberculosis Committee on Prophylaxis : Efficacy of various durations of isoniazid preventive therapy for tuberculosis : five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ, 60 : 555-564, 1982
PubMed
31) Finch CK, et al : Rifampin and rifabutin drug interactions : an update. Arch Intern Med, 162 : 985-992, 2002
PubMed
32) 倉島篤行 : 7年ぶりに行われた肺非結核性抗酸菌症全国調査結果について. 結核, 90 (7) : 605-606, 2015
Medical*Online
33) Daley CL, et al : Treatment of Nontuberculous Mycobacterial Pulmonary Disease : An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline : Executive Summary. Clin Infect Dis : doi : 10.1093/cid/ciaa241, 2020
 
34) 日本結核病学会非結核性抗酸菌症対策委員会 : 肺非結核性抗酸菌症診断に関する指針-2008年. 結核, 83 (7) : 525-526, 2008 https://www.kekkaku.gr.jp/commit/ntm/200804sisin.pdf
 
35) Haworth CS & Floto RA : Introducing the new BTS Guideline : Management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 72 : 969-970, 2017
PubMed
36) Piersimoni C & Scarparo C : Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients. Lancet Infect Dis, 8 : 323-334, 2008
PubMed
37) Kahana LM, et al : Mycobacterium avium complex infection in an immunocompetent young adult related to hot tub exposure. Chest, 111 : 242-245, 1997
 
38) 「Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV」, AIDS info, 2020
 
39) Tomblyn M, et al : Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients : a global perspective. Biol Blood Marrow Transplant, 15 : 1143-1238, 2009
PubMed
40) Taplitz RA, et al : Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression : ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol, 36 : 3043-3054, 2018
PubMed
41) Fishman JA & Gans H : Pneumocystis jiroveci in solid organ transplantation : Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant, 33 : e13587, 2019
PubMed
42) 猪熊茂子, 他 : 免疫疾患に合併するニューモシスティス肺炎の予防規準. 「免疫疾患の合併症とその治療法に関する研究 平成16年度 総括研究報告書」 (橋本博史/総括), 厚生労働省, 2004
 
43) Thomas CF Jr & Limper AH : Pneumocystis pneumonia. N Engl J Med, 350 : 2487-2498, 2004
PubMed
44) Kovacs JA & Masur H : Evolving health effects of Pneumocystis : one hundred years of progress in diagnosis and treatment. JAMA, 301 : 2578-2585, 2009
PubMed
45) Green H, et al : Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients : systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc, 82 : 1052-1059, 2007
PubMed
46) Harigai M, et al : Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med, 357 : 1874-1876, 2007
PubMed
47) Godeau B, et al : Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis, 54 : 991-994, 1995
 
48) Lertnawapan R, et al : Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int, 29 : 491-496, 2009
PubMed
49) Landewe RB, et al : EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis, 79 : 851-858, 2020
PubMed
50) Ito S & Koren G : Estimation of fetal risk from aerosolized pentamidine in pregnant healthcare workers. Chest, 106 : 1460-1462, 1994
PubMed
51) Stern RS : Clinical practice. Exanthematous drug eruptions. N Engl J Med, 366 : 2492-2501, 2012
PubMed
52) Delanaye P, et al : Trimethoprim, creatinine and creatinine-based equations. Nephron Clin Pract, 119 : c187-93 ; discussion c193, 2011
 
53) Suyama Y, et al : Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus : A retrospective cohort study. Mod Rheumatol, 26 : 557-561, 2016
PubMed
54) Maezawa R, et al : Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases. Mod Rheumatol, 23 : 62-70, 2013
PubMed
55) Absar N, et al : Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients. J Allergy Clin Immunol, 93 : 1001-1005, 1994
PubMed
56) 陶山恭博, 他 : 膠原病治療時のニューモシスチス肺炎予防に用いるST合剤によるアレルギーへの対処法は?. 週刊日本医事新報, 5020 : 50, 2020
 
57) 「Dubois' Lupus Erythematosus & Related Syndromes, 9th ed」 (Wallace DJ & Hahn BH/eds), 2019
 
58) van de Wetering MD, et al : Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients : a systematic review of randomised controlled trials. Eur J Cancer, 41 : 1372-1382, 2005
PubMed
P.250 掲載の参考文献
1) De Cock D, Hyrich K : Malignancy and rheumatoid arthritis : Epidemiology, risk factors and management. Best Pract Res Clin Rheumatol. 32 (6) : 869-886, 2018
PubMed
2) Strangfeld A, et al : Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther, 12 : R5, 2010
 
3) Silva-Fernandez L, et al : The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab : results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology (Oxford), 55 : 2033-2039, 2016
PubMed
4) Raaschou P, et al : Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis : A Nationwide Population-Based Cohort Study. Ann Intern Med, 169 : 291-299, 2018
PubMed
5) Scott FI, et al : Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatol, 152 : 164-172, 2016
PubMed
6) Mercer LK, et al : The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis : longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 71 : 869-874, 2012
PubMed
7) Raaschou P, et al : TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis : a nationwide cohort study. Ann Rheum Dis, 74 : 2137-2143, 2015
PubMed
8) Mamtani R, et al : Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease : A Cohort Study. Arthritis Rheumatol, 68 : 2403-2411, 2016
PubMed
9) Phillips C, et al : Tumor Necrosis Factor Inhibition and Head and Neck Cancer Recurrence and Death in Rheumatoid Arthritis. PLoS One, 10 : e0143286, 2015
PubMed
10) Singh JA, Saag KG, Bridges SL Jr et al. : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 68 (1) : 1-26, 2016
PubMed
11) Lopez-Olivo MA, Colmegna I, Karpes Matusevich AR et al. : Systematic Review of Recommendations on the Use of Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer. Arthritis Care Res (Hoboken). 72 (3) : 309-318, 2020
PubMed
P.255 掲載の参考文献
1) Flint J, et al : BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I : standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford), 55 : 1693-1697, 2016
PubMed
2) Gotestam Skorpen C, et al : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis, 75 : 795-810, 2016
PubMed
3) Levy RA, et al : Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev, 15 : 955-963, 2016
PubMed
4) Flint J, et al : BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II : analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford), 55 : 1698-1702, 2016
PubMed
5) Giles I, et al : Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nat Rev Rheumatol, 15 : 391-402, 2019
PubMed
P.261 掲載の参考文献
1) Goodman SM, et al : 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol, 69 : 1538-1551, 2017
PubMed
2) MacKenzie CR & Goodman SM : Stress Dose Steroids : Myths and Perioperative Medicine. Curr Rheumatol Rep, 18 : 47, 2016
PubMed
3) Coursin DB & Wood KE : Corticosteroid supplementation for adrenal insufficiency. JAMA, 287 : 236-240, 2002
PubMed
4) Cohn SL : Preoperative Evaluation for Noncardiac Surgery. Ann Intern Med, 165 : ITC81-ITC96, 2016
PubMed
5) Pfeifer K, et al : Update in perioperative medicine. J Gen Intern Med, 25 : 1346-1351, 2010
PubMed
6) Goodman SM & Figgie MA : Arthroplasty in patients with established rheumatoid arthritis (RA) : Mitigating risks and optimizing outcomes. Best Pract Res Clin Rheumatol, 29 : 628-642, 2015
PubMed
7) George MD, et al : Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty : A Cohort Study. Ann Intern Med, 170 : 825-836, 2019
PubMed
P.266 掲載の参考文献
1) Soubrier M, et al : Elderly-onset rheumatoid arthritis. Joint Bone Spine, 77 : 290-296, 2010
PubMed
2) Lahaye C, et al : Management of inflammatory rheumatic conditions in the elderly. Rheumatology (Oxford), 58 : 748-764, 2019
PubMed
3) 「関節リウマチ診療ガイドラインJCR2014に基づく一般医向け診療ガイドライン」 (宮坂信之, 山中寿/文責), 2014 https://www.ryumachi-jp.com/info/RA_guideline.pdf
 
4) 日本リウマチ友の会HP http://www.nrat.or.jp/index.html
 
5) 日本リウマチ財団HP http://www.rheuma-net.or.jp/index.html
 
P.273 掲載の参考文献
1) Lopez A, et al : Vaccination recommendations for the adult immunosuppressed patient : A systematic review and comprehensive field synopsis. J Autoimmun, 80 : 10-27, 2017
PubMed
2) 日本呼吸器学会ワクチン検討WG 委員会/日本感染症学会ワクチン委員会合同委員会 : 65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方 (第3版 2019-10-30), 2019
 
3) Friedman MA & Winthrop K : Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol, 28 : 330-336, 2016
PubMed
4) Rubin LG, et al : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis, 58 : 309-318, 2014
PubMed
5) Dooling KL, et al : Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 67 : 103-108, 2018
PubMed
6) Singh JA, et al : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken), 68 : 1-25, 2016
 
7) Furer V, et al : 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79 : 39-52, 2019
PubMed
P.278 掲載の参考文献
1) Agca R, et al : EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update. Ann Rheum Dis, 76 : 17-28, 2017
PubMed
2) Fanouriakis A, et al : 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis, 78 : 736-745, 2019
PubMed
3) Ward R : Identifying and assessing benefit-risk in primary care--a family physician's perspective. Rheumatology (Oxford), 49 Suppl 2 : ii18-ii23, 2010
PubMed
4) 「EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots」 (European Medical Agency), 2020 https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_en.pdf
 
5) Semb AG, et al : Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol, 16 : 361-379, 2020
PubMed
6) Kolasinski SL, et al : 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol, 72 : 220-233, 2020
PubMed
7) Solomon DH, et al : Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis : A Randomized Clinical Trial. Arthritis Rheumatol, 70 : 537-546, 2018
PubMed
8) Agca R, et al : EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update. Ann Rheum Dis, 76 : 17-28, 2017
PubMed
9) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis, 79 : 685-699, 2020
PubMed
10) Fanouriakis A, et al : 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis, 78 : 736-745, 2019
PubMed
11) 「脳心血管病予防に関する 包括的リスク管理チャート 2019年版について」 (脳心血管病協議会/編), 日本内科学会雑誌, 108 : 1024-1074, 2019
 

書評

最近チェックした商品履歴

Loading...